- Home
- NUV vs IMCR Comparison
NUV vs IMCR Comparison
Compare NUV & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUV
- IMCR
- Stock Information
- Founded
- NUV 1987
- IMCR 2008
- Country
- NUV United States
- IMCR United Kingdom
- Employees
- NUV N/A
- IMCR N/A
- Industry
- NUV Trusts Except Educational Religious and Charitable
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NUV Finance
- IMCR Health Care
- Exchange
- NUV Nasdaq
- IMCR Nasdaq
- Market Cap
- NUV 1.8B
- IMCR 1.5B
- IPO Year
- NUV N/A
- IMCR 2021
- Fundamental
- Price
- NUV $8.53
- IMCR $31.34
- Analyst Decision
- NUV
- IMCR Buy
- Analyst Count
- NUV 0
- IMCR 10
- Target Price
- NUV N/A
- IMCR $58.13
- AVG Volume (30 Days)
- NUV 464.9K
- IMCR 560.7K
- Earning Date
- NUV 01-01-0001
- IMCR 08-07-2025
- Dividend Yield
- NUV 3.96%
- IMCR N/A
- EPS Growth
- NUV N/A
- IMCR N/A
- EPS
- NUV N/A
- IMCR N/A
- Revenue
- NUV N/A
- IMCR $333,581,000.00
- Revenue This Year
- NUV N/A
- IMCR $26.82
- Revenue Next Year
- NUV N/A
- IMCR $8.15
- P/E Ratio
- NUV N/A
- IMCR N/A
- Revenue Growth
- NUV N/A
- IMCR 25.75
- 52 Week Low
- NUV $7.86
- IMCR $23.15
- 52 Week High
- NUV $9.08
- IMCR $41.54
- Technical
- Relative Strength Index (RSI)
- NUV 45.95
- IMCR 40.28
- Support Level
- NUV $8.43
- IMCR $35.10
- Resistance Level
- NUV $8.62
- IMCR $37.56
- Average True Range (ATR)
- NUV 0.06
- IMCR 1.74
- MACD
- NUV 0.00
- IMCR -0.79
- Stochastic Oscillator
- NUV 50.00
- IMCR 0.75
About NUV Nuveen Municipal Value Fund Inc.
Nuveen Municipal Value Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations issued by state and local government authorities or certain U.S. territories.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.